Navigation Links
Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis
Date:5/16/2014

SOUTH PLAINFIELD, NJ May 16, 2014 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) were published in Lancet Respiratory Medicine. The results demonstrated positive trends in both the primary endpoint, lung function as measured by relative change in % predicted FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations. The collective data from this trial, including retrospective and subgroup analyses support the conclusion that ataluren was active and showed clinically meaningful improvements over placebo in these trials.

"The overall data from this trial are promising. Patients on ataluren experienced fewer pulmonary exacerbations and showed a stabilization in their FEV1 results, particularly in the subgroup of patients that did not use chronic inhaled aminoglycosides. Such stabilization of disease is an important clinical endpoint, particularly for this patient population that has one of the most severe forms of CF. CF patients with nonsense mutations do not produce any functional CFTR protein and therefore generally have a more severe form of cystic fibrosis. Current treatments for nonsense mutation cystic fibrosis focus on alleviating symptoms and reducing infections, whereas ataluren targets the underlying cause of disease," stated Michael Konstan, M.D., lead study investigator and Chairman of Pediatrics at from University Hospitals Rainbow Babies and & Children's Hospital in Cleveland, Ohio.

The Phase 3 double-blind, placebo-controlled study, which was conducted across 11 countries, compared ataluren (n=116) to placebo (n=116) in nmCF patients. The primary endpoint, the relative change from baseline in %-predicted FEV1 at 48 weeks, showed a positive trend favoring ataluren versus placebo, and a larger effect in patients not receiving chronic inhaled tobramycin. In the
'/>"/>

Contact: Katelyn McCarthy
katelyn.mccarthy@uhhospitals.org
216-767-8582
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
2. Celldexs Phase 1 study of CDX-1401 published in Science Translational Medicine
3. Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
4. Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer promising
5. North Shore-LIJ Completes Last Phase of $50M Upgrade of its Diagnostic Imaging Systems, $12M for GE Low-Dose CT Scanners to Reduce Patients’ Radiation Exposure
6. Stryker Hip Lawsuit News: Phase II of Mediation Set to Begin in Stryker Hip Recall Litigation Underway in New Jersey State Court, Bernstein Liebhard LLP Reports
7. LFoundry Rousset LF 110 Flash Technology Enters Industrial Phase
8. “Final Phase Fat Loss” Introduces To People An Innovative Bodyweight Training Program – Vinamy
9. CS Caregiver University Announces Its First Phase of Inductive Training for the Month of October
10. Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Novel Agents for Cancer Diagnosis and Targeted Therapy
11. For first time, drug developed based on zebrafish studies passes Phase I clinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
(Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... Lalvani and colleagues from University of Oxford, UK has found ... which BCG vaccination which is administered world wide for children’s ... an effective treatment in patients with TB infection. The researchers ... children, of which 770 children’s had BCG scar, as the ...
... as 150 million Indians, who comprise about 15 percent ... arthritis, according to latest reports by doctors//. This figure ... the meeting held in conjunction with World Arthrirtis Day. ... is also being conducted to create awareness on handling ...
... A study conducted to evaluate the effectiveness of environmental ... intervention program would be a cost effective way to ... study was conducted among 900 children suffering from mild ... on six major classes of allergens that trigger asthma ...
... researchers at the University of Minnesota have managed to create ... laboratory in what could be a revolutionary method of treating ... discovery is to appear in the October 15 issue of ... "natural killer" cells from the stem cells in the laboratory. ...
... needed. Ideally, such products should have antimicrobial and ... a role in the reduction of sexually// transmitted ... ,Most of the spermicidal products being ... ingredient, which do not provide any protection against ...
... the inability of a man to achieve or maintain an ... his partner. Most men experience this at some point in ... affected by it. Some men, however, experience chronic, complete ED ... to a new study in the October 18 issue of ...
Cached Medicine News:Health News:BCG vaccine for both Protection and treatment of Tuberculosis 2Health News:Dermaseptins: Potent vaginal contraceptives 2Health News:Erectile dysfunction: an early warning sign of clinically silent coronary artery disease? 2
(Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... N.C. , Feb. 4 Gorbec Pharmaceutical ... prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory ... expand Gorbec,s current services for analytical method development and ... its U.S. customer base as well as develop a ...
... , Feb. 4 Genoptix, Inc. (Nasdaq: GXDX ), ... report its financial results for the fourth quarter and full-year 2009 after ... 2010 . , A conference call hosted by President and CEO, ... will take place on the same day at 2:00pm PST ...
Cached Medicine Technology:Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China 2Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results 2Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results 3
...
...
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in ...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Medicine Products: